Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis
Fischer, R., Trudgian, D. C., Wright, C., Thomas, G., Bradbury, L. A., Brown, M. A., Bowness, P., & Kessler, B. M. (2012) Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis. Molecular and Cellular Proteomics, 11(2).
Ankylosing Spondylitis (AS) is a common inflammatory rheumatic disease with a predilection for the axial skeleton, affecting 0.2% of the population. Current diagnostic criteria rely on a composite of clinical and radiological changes, with a mean time to diagnosis of 5 to 10 years. In this study we employed nano liquid-chromatography mass spectrometry analysis to detect and quantify proteins and small compounds including endogenous peptides and metabolites in serum from 18 AS patients and nine healthy individuals. We identified a total of 316 proteins in serum, of which 22 showed significant up- or down-regulation (p < 0.05) in AS patients. Receiver operating characteristic analysis of combined levels of serum amyloid P component and inter-α-trypsin inhibitor heavy chain 1 revealed high diagnostic value for Ankylosing Spondylitis (area under the curve = 0.98). We also depleted individual sera of proteins to analyze endogenous peptides and metabolic compounds. We detected more than 7000 molecular features in patients and healthy individuals. Quantitative MS analysis revealed compound profiles that correlate with the clinical assessment of disease activity. One molecular feature identified as a Vitamin D3 metabolite-(23S,25R)-25-hydroxyvitamin D3 26,23-peroxylactone-was down-regulated in AS. The ratio of this vitamin D metabolite versus vitamin D binding protein serum levels was also altered in AS as compared with controls. These changes may contribute to pathological skeletal changes in AS. Our study is the first example of an integration of proteomic and metabolomic techniques to find new biomarker candidates for the diagnosis of Ankylosing Spondylitis
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||25 hydroxycolecalciferol 26, 23 peroxylactone, amyloid P component, biological marker, colecalciferol, inter alpha trypsin inhibitor heavy chain 1, trypsin, unclassified drug, vitamin D binding protein, adult, ankylosing spondylitis, article, clinical article, controlled study, correlation analysis, down regulation, female, human, liquid chromatography, male, mass spectrometry, metabolite, metabolomics, priority journal, protein blood level, proteomics, quantitative analysis, receiver operating characteristic, upregulation|
|Divisions:||Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2012 The American Society for Biochemistry and Molecular Biology, Inc.|
|Deposited On:||21 Oct 2015 01:53|
|Last Modified:||23 Feb 2016 04:36|
Repository Staff Only: item control page